Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01624727 · ClinicalTrials.gov registry record · NA

Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids

A NA study of Metabolic Syndrome and Coronary Heart Disease, sponsored by Beth Israel Deaconess Medical Center.

Completed
Registry status
NA
Development phase
338
Enrollment target
2
Study locations

NCT01624727 is a NA study of Metabolic Syndrome and Coronary Heart Disease that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 338 participants, below the 1,202-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01624727, a NA study of Metabolic Syndrome and Coronary Heart Disease, has completed, sponsored by Beth Israel Deaconess Medical Center.

COMPLETED
Registry status
NA
Development phase
338 participants
Enrollment target
2
Study locations

Study Summary

The purpose of the study is to target inflammation to reduce progression of noncalcified plaque in the coronary arteries using omega-3 fatty acid supplementation compared to standard of care.

Interventions

  • DIETARY_SUPPLEMENT Omega 3 acid ethyl esters

Study Locations (2)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • South Shore Medical Group - Milton

Trial Details

FieldValue
Enrollment Target 338 participants
Start Date 2009-06
Est. Completion 2015-01-15
Phase NA

What the Registry Record Tells You About NCT01624727

The ClinicalTrials.gov registry entry for NCT01624727 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 338 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,202-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (72% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metabolic Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Omega 3 acid ethyl esters is the first listed.

NCT01624727 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01624727 about?

NCT01624727 is a clinical study titled "Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids". The purpose of the study is to target inflammation to reduce progression of noncalcified plaque in the coronary arteries using omega-3 fatty acid supplementation compared to standard of care.

What is the current status of trial NCT01624727?

This trial is currently completed. It is a NA study. The enrollment target is 338 participants. The study started on 2009-06. Estimated completion is 2015-01-15.

What conditions does trial NCT01624727 study?

This clinical trial studies the following conditions: Metabolic Syndrome, Coronary Heart Disease.

What interventions are being tested in trial NCT01624727?

The interventions under investigation include: Omega 3 acid ethyl esters (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01624727?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01624727 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metabolic Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.